Neuroprotective agents target molecular mechanisms of disease in ALS

Y Zhu, A Fotinos, LLJ Mao, N Atassi, EW Zhou… - Drug Discovery …, 2015 - Elsevier
Highlights•Comparing agents used in ALS animal models by onset, survival and muscle
damage.•Agents are organized by individual mechanisms and effects summarized.•Analysis …

Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning

V Kumar, A Islam, MI Hassan, F Ahmad - European Journal of Medicinal …, 2016 - Elsevier
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease associated with
motor neuron degeneration, muscle weakness, paralysis and finally death. The proposed …

Amyotrophic lateral sclerosis: current therapeutic perspectives

V Kumar, T Kashav, MI Hassan - Pathology, prevention and therapeutics …, 2019 - Springer
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, characterized by
progressive motor neuron degeneration, muscle weakness, paralysis, and ultimately death …

Translational Therapeutic Str ategies in Amyotrophic Lateral Sclerosis

H Ryu, RJ Ferrante - Mini Reviews in Medicinal Chemistry, 2007 - ingentaconnect.com
Amyotrophic lateral sclerosis (ALS) is a clinically severe and fatal neurodegenerative
disease characterized by a loss of both upper and lower motor neurons, resulting in …

New therapeutic targets for amyotrophic lateral sclerosis

M Kuzma-Kozakiewicz, H Kwiecinski - Expert opinion on …, 2011 - Taylor & Francis
Introduction: Amyotrophic lateral sclerosis (ALS) is one of the most devastating neurological
disorders, affecting approximately half a million people worldwide. Currently there is no cure …

Roots to start research in amyotrophic lateral sclerosis: molecular pathways and novel therapeutics for future

D Harikrishnareddy, S Misra, S Upadhyay… - Reviews in the …, 2015 - degruyter.com
Amyotrophic lateral sclerosis (ALS) is a devastating neurological disease that rapidly
progresses from mild motor symptoms to severe motor paralysis and premature death. There …

Prospects for the pharmacotherapy of amyotrophic lateral sclerosis: old strategies and new paradigms for the third millennium

BW Festoff, Z Suo, BA Citron - CNS drugs, 2003 - Springer
Biomedical researchers interested in amyotrophic lateral sclerosis (ALS) must invoke newly
developing technologies if we are to discover pharmaceutical treatments that will help a …

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation

RJ Mead, N Shan, HJ Reiser, F Marshall… - Nature Reviews Drug …, 2023 - nature.com
Amyotrophic lateral sclerosis (ALS) is a devastating disease caused by degeneration of
motor neurons. As with all major neurodegenerative disorders, development of disease …

Novel therapeutic targets for amyotrophic lateral sclerosis

G Batra, M Jain, RS Singh, AR Sharma… - Indian Journal of …, 2019 - journals.lww.com
Amyotrophic lateral sclerosis (ALS) is an untreatable and fatal neurodegenerative disease
that is identified by the loss of motor neurons in the spinal cord, brain stem, and motor cortex …

Treatment of amyotrophic lateral sclerosis: lessons learned from many failures

PH Özdinler, RB Silverman - ACS Medicinal Chemistry Letters, 2014 - ACS Publications
Amyotrophic lateral sclerosis (ALS) is one of the most complex neurodegenerative diseases,
involving both cortical and spinal components of motor neuron circuitry and non-neuronal …